CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤治疗的最新进展：溶瘤病毒与新兴的未来策略
英文原题：Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.
查看英文原题
Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤是侵袭性最强的恶性脑肿瘤。标准治疗方案和传统免疫疗法无法显著延长胶质母细胞瘤患者长期生存，因此疗效有限。溶瘤病毒（OV）可能是一种有效替代方法。将 OV 与一些现代治疗方案联合，也可能给胶质母细胞瘤患者带来显著获益。本文综述胶质母细胞瘤病毒疗法，介绍多种 OV 及其与其他疗法的联合应用。个体化使用 OV 并与其他治疗选择联合，将成为重要研究方向，旨在为胶质母细胞瘤开发最有效的治疗方案。
展开英文摘要原文
Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment protocols and traditional immunotherapy are poorly effective as they do not significantly increase the long-term survival of glioblastoma patients. Oncolytic viruses (OVs) may be an effective alternative approach. Combining OVs with some modern treatment options may also provide significant benefits for glioblastoma patients.
Here we review virotherapy for glioblastomas and describe several OVs and their combination with other therapies. The personalized use of OVs and their combination with other treatment options would become a significant area of research aiming to develop the most effective treatment regimens for glioblastomas.
论文信息
- 作者
- Hamad A、Yusubalieva GM、Baklaushev VP、Chumakov PM、Lipatova AV
- 单位
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.Russia
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Viruses2023 Feb 16
- 原文标识
- PubMed 36851761 · DOI 10.3390/v15020547
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →